🕐27.06.11 - 08:54 Uhr

=?UTF-8?Q?NEW=20SAB=20MEMBER=20DR=?UTF-8?Q?.=20ANDR =?UTF-8?Q?EWS=20BOOSTS=20FAR
SIGHT=20=?UTF-8?Q?WITH=2030 =?UTF-8?Q20YEARS=E2=80=99=20BIOTECH=20EX=?UTF-8?Q?PERIE NCE



London, June 27, 2011 - The biotech company Farsight Bioscience Ltd.

announces the appointment of Dr.

William Andrews to its Scientific Advisory Board (SAB) that works closely with the company to support development of the Farsight product pipeline. Dr.

William Andrews from Sierra Science is one of the world’s leading scientists in extending youth and reversing aging.

He has worked in the biotech industry for almost 30 years, focusing the last 17 years on finding ways to extend human lifespan through the intervention of telomere shortening in human cells.

In 1981 Dr.

Andrews earned his Ph.D.

in Molecular and Population Genetics at the University of Georgia.

He was a Senior Scientist at Armos Corporation and Codon Corporation, Director of Molecular Biology at Codon and at Geron Corporation, and Director of Technology Development at EOS Biosciences.

While Director of Molecular Biology at Geron Corporation from 1993 to 1997, Dr.

Andrews was one of the principal discoverers of both the RNA and protein components of human telomerase and was awarded 2nd place as "United States’ Inventor of the Year" in 1997 for this work.

He is presently a named inventor on 42 US issued telomerase patents and has collaborated with Elizabeth Blackburn and Carol Greider, 2009 Nobel Prize Winners and world-renown Molecular Biology Research Scientists.

“As telomerase treatment will be one of our future focus areas and key investments, we are obviously pleased that Dr.

Andrews has chosen to work with us in Farsight”, says Erling Refsum, Chief Executive Officer of Farsight Bioscience: “And we feel pretty sure that this cooperation will be lucrative - both for our company and our investors.” “My dedication to telomerase research has brought me to this opportunity.

I almost can’t wait to start working with all you talented colleagues and create results that could potentially improve the lives of people all over the world”, replies Dr.

Andrews.
About Farsight Bioscience Limited Farsight Bioscience’s core activities centre on developing drugs in large markets with significant growth that offer the potential to become blockbusters.

Its focus is on primary care drugs for the prevention and treatment of human diseases.

So far three indication areas that satisfy these criteria have been identified: Metabolic Disorders (Obesity and Diabetes-2); inflammatory diseases (arthritis, bowel diseases); cardiovascular (anti-atherosclerotic and anti-inflammatory).

Through the use of outsourcing and strategic partnerships Farsight runs a lean as well as cost and time-efficient drug development engine.

The objective is to exit any research project as soon as a commercially viable exit is found.

The intention is to collaborate with other biotech entities to share research and cost.

Also, the aim is to create value through being cost and time-efficient as well as industrious and systematic, operating on the prime spot of value creation between drug discovery and phase III clinical studies.

The Company’s mission is to make safe and effective drugs available to the public, quickly and at affordable prices.

See also: www.farsightbioscience.com. For further information: Farsight Bioscience Limited 29 Harley Street London, W1G 9QR England Tel.: +44 (0)20 7377 1489 Email: Disclaimer – forward-looking statements The Farsight Bioscience Limited communications contains certain statements regarding future events that express the beliefs and expectations of management.

Such statements are based on current expectations, estimates and forecasts on the part of company management and imply various known and unknown risks and uncertainties, which may result in actual earnings, the financial situation, growth or performance to be different from the estimates expressed or implied in the forward-looking statements.

Farsight is of the opinion that the expectations reflected in the forward-looking statements are appropriate.

However, it cannot guarantee that these expectations will materialize.

Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ from those projected in the forward-looking statements, including the risks that actual results may differ from those projected in the forward-looking statements.

Projected events in this press release may not occur due to unforeseen circumstances, various factors, and other risks.

Farsight Bioscience Limited does not assume any obligation to update these forward-looking statements or adapt them to future events and developments.
NEWSLETTER REGISTRIERUNG: Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach: http://www.irw-press.com/alert_subscription.php?lang=en&isin=GB00B60Q3R70 Mitteilung übermittelt durch IRW-Press.com.

Für den Inhalt ist der Aussender verantwortlich.

Kostenloser Abdruck mit Quellenangabe erlaubt.



Products & Services | Jobs